U.S. Markets closed

See what the IHS Markit Score report has to say about Johnson & Johnson.

IHS Markit

Johnson & Johnson

NYSE:JNJ

Score: Negative (25)

7 days at current score.

Downgraded from Neutral on June 26th 2018

View full report here!

Summary


  • This company ranked negatively compared to the Healthcare sector despite only 1 negative IHS Markit Category
  • Perception of the company's creditworthiness is neutral
  • ETFs holding this stock have seen outflows over the last one-month
  • Bearish sentiment is low


Bearish sentiment

Short interest | Positive

Short interest is extremely low for JNJ with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ.

Money flow

ETF/Index ownership | Negative

ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding JNJ totaled $2.41 billion. Additionally, the rate of outflows appears to be accelerating.

Economic sentiment

PMI by IHS Markit | Neutral

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is very weak relative to the trend shown over the past year. In fact, it has been weak enough that the rate of expansion may accelerate in the coming months.

Credit worthiness

Credit default swap | Neutral

The current level displays a neutral indicator. JNJ credit default swap spreads are within the middle of their range for the last three years.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.